MedTrace Logo

A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

NCT00210340 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-03-30

No results posted yet for this study

Summary

The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.

Conditions

  • Lymphoma, B Cell

Interventions

DRUG

intrathecal rituximab

Sponsors & Collaborators

  • International Extranodal Lymphoma Study Group (IELSG)

    lead OTHER

Principal Investigators

  • Annarita Conconi, MD · International Extranodal Lymphoma Study Group/Hematology Division. University Amedeo Avogadro. Novara

  • Andres JM Ferreri, MD · Radiochemotherapy San Raffaele Hospital. Milan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210340 on ClinicalTrials.gov